Home Members Only Search About Us Store FASEB Member Directory

 the-aps.org>meetings>eb

advertising
awards
careers and mentoring
chapters
committees
education
meetings
membership
news archives
press room
public affairs
publications
sections and groups
sites of interest
trainees

9560 rockville pike, bethesda, MD 20814-3991
 

 


Advances in Ion Channel Physiology
Sponsored by the APS Liaison with Industry Committee

Sun. April 2 — 10:30 AM-12:30 PM
 
Chaired:

William J. Martin, Theravance, Inc.

This symposium will feature presentations from scientists working in industry. Presenters will highlight the development and use of novel technologies and describe the ways in which these approaches are advancing our understanding of ion channel function and transforming the treatment of a variety of disease states. Dr. Krafte will review the contribution of ion channels to the physiology and pathophysiology of pain and will describe the therapeutic potential of newly identified ion channel modulators. Dr. Fermini’s presentation will review the role of ion channel in cardiac physiology from the perspective of treating cardiac arrhythmias as well as improving the safety of novel small molecule therapies. Dr. VanGoor will present work on the identification of small molecules that modulate the kinetics or promote proper folding and trafficking of channels with the most common mutations for Cystic Fibrosis. Dr. Sher will speak on two new classes of nicotinic allosteric potentiators that have recently discovered and characterized which may have broad therapeutic utility across a range of indications.
 

10:30 AM

Ion Channels in Pain Pathways:  Physiological Roles and Therapeutic Potential.
Doug Krafte
, Icagen, Inc., Durham, NC
 

11:00 AM

Ion channels and Cardiac Arrhythmias.
Bernard Fermini
, Pfizer Global Research, Groton, CT
 

11:30 AM

Rescue of mutant cystic fibrosis transmembrane conductance regulator (CFTR) function by therapeutic agent.
Fred VanGoor
, Vertex Pharmaceuticals Inc., San Diego
 

12:00 Noon

Therapeutic potential of positive allosteric modulators of glutamate AMPA receptors.
Eric S. Nisenbaum,  Eli Lilly & Co.